Is Now a Good Time to Sell a Hospice Business?

Yes — 2026 is still a favorable time to sell a hospice business, with strong operators commanding 8x-12x EBITDA. The sector remains attractive because of aging demographics, commercial payor expansion, and continued PE appetite, but CMS's 2026 Final Rule and the HOPE (Hospice Outcomes and Patient Evaluation) data collection requirement are adding 60-90 days to pre-sale preparation. Smaller hospices trade at 4x-6x, mid-market at 6x-9x, and regional platforms at 9x-12x.

Typical Multiple: 4x-12x EBITDA | Timeline: 6-12 months | Sweet Spot: $2M-$15M revenue, Medicare certified beyond 36-month window | Prep Add: +60-90 days for HOPE compliance

Why Is 2026 Still a Good Time to Sell?

Three things keep the hospice M&A market favorable. First, aging demographics — the 75+ population is growing roughly 3% annually, and hospice utilization rates keep climbing as awareness expands. Second, commercial payor expansion — Medicare Advantage now covers over 50% of Medicare lives, and MA plans are contracting with hospice providers at rates that often exceed traditional Medicare per-diem, adding margin durability. Third, buyer capital — Enhabit, BrightSpring, Addus HomeCare, Humana's CenterWell, Amedisys, and Aveanna all have active hospice mandates, plus PE platforms from Webster Equity, H.I.G. Capital, Nautic Partners, and Vistria Group. Strong assets with scalable clinical infrastructure still run competitive processes with 5-8 LOIs. For broader benchmarks, review the hospice valuation framework.

The counter-balance: CMS's 2026 Final Rule implementation and the HOPE data collection tool have added complexity. Buyers now scrutinize HOPE timepoint data, symptom impact scores, and section Z documentation during diligence. Hospices that haven't cleaned up their HOPE submissions are losing 30-60 days in diligence and sometimes a turn of multiple. The 36-month CHOW rule also continues to matter — if you're a recent acquirer still inside the 36-month window, you'll need to factor that into timing and buyer selection, since adjacent healthcare service sectors like home health face the same CHOW dynamics.

"I had a hospice seller last year at $11M revenue who delayed going to market by four months specifically to clean up HOPE data. That prep cost her about $30K in consulting fees. When the deal closed, her QofE came back cleaner than her last acquirer had ever seen, and the buyer paid her 9.1x EBITDA instead of the 8x I think she would have gotten going in raw. That's real money for three months of work. Hospice sellers in 2026 can't skip the HOPE cleanup."

— John M. Salony, Business Broker

Find Out What Your Hospice Business Is Worth

Start with the free valuation calculator to see what your hospice is worth in today's market. From there we can set up a confidential consultation to walk through HOPE readiness, buyer fit, and timing for your agency.

Schedule a Confidential Consultation

Frequently Asked Questions

Why Is 2026 Still a Good Time to Sell?
Three things keep the hospice M&A market favorable. First, aging demographics — the 75+ population is growing roughly 3% annually, and hospice utilization rates keep climbing as awareness expands among patients, families, and referring physicians. Second, commercial payor expansion — Medicare Advantage now covers over 50% of Medicare lives, and MA plans are contracting with hospice providers at rates that often exceed traditional Medicare per-diem, adding margin durability. Third, buyer capital — Enhabit, BrightSpring, Addus HomeCare, Humana's CenterWell, Amedisys, and Aveanna all have active hospice mandates, plus PE platforms from Webster Equity, H.I.G. Capital, Nautic Partners, and Vistria Group. Strong assets with scalable clinical infrastructure still run competitive processes with 5-8 LOIs.
What's Changed in 2026 That Sellers Need to Know?
The biggest change is CMS's 2026 Final Rule implementation and the HOPE (Hospice Outcomes and Patient Evaluation) data collection tool, which replaced the Hospice Item Set. Buyers now scrutinize HOPE timepoint data (admission, 3-day-before-death, discharge), symptom impact scores, section Z documentation, and socio-demographic items during diligence. Hospices that haven't cleaned up HOPE submissions are losing 30-60 days in diligence and sometimes a turn of multiple. The 36-month CHOW rule also continues to matter — if you're a recent acquirer still inside the 36-month window, you'll need to factor that into timing and buyer selection, since transferring the Medicare certification before the window expires can trigger re-survey requirements that delay close. Hospices should plan for an extra 60-90 days of pre-market preparation compared to pre-2025 deals.